Signed in as:
filler@godaddy.com
Paul Bragoli
Paul brings more than 20 years of experience across pharmaceuticals and medical devices, specializing in market access, payer strategy, and commercialization. He has led high-performing teams through complex commercial, Medicare, and Medicaid environments, supporting successful launches in retail pharmacy, prescription digital therapeutics, and bioengineered products. His work centers on designing strategic partnerships and payer solutions that expand patient access and strengthen product value.
Paul has advised startups and emerging biopharma companies on pricing, contracting, coverage strategy, and pre-launch planning—guiding organizations from early development through commercial execution. His foundation in clinical behavioral health informs a deeply patient-centric perspective, ensuring that operational and payer strategies are grounded in real-world impact.
Recognized for his collaborative leadership style, Paul excels at aligning cross-functional stakeholders and driving change management to support shared goals. He is based in San Diego, where he and his wife are raising their three daughters, and remains passionate about advancing healthcare through innovative access solutions and meaningful engagement.
Paul Bragoli
W.H. Alvin Mok
Alvin is a commercial operations leader known for transforming how emerging and established biopharmaceutical companies bring therapies to market. With deep experience across oncology, cardiovascular disease, and prescription digital therapeutics, he builds commercialization infrastructure that aligns strategy, analytics, and field execution into a cohesive, high-performing engine.
Throughout his career, Alvin has led major product launches, integrated commercial functions during mergers, and transformed operations for companies ranging from startups to global biopharma. His expertise includes designing scalable go-to-market models, optimizing field force structures, developing fit-for-purpose operational functions and data ecosystems that drive commercial results.
He is recognized for simplifying complexity, linking data, technology, and cross-functional teams to accelerate execution. His work has built teams from the group up, reshaped field operations for more than 1,000 representatives, built analytics platforms that deliver real-time insights, and improved data governance and integration across Sales, Marketing, Market Access, and Medical.
At ElevEx Bio, Alvin brings this commercialization and operational transformation expertise to pre-clinical and emerging biopharma clients. He helps founders and lean teams build launch-ready capabilities, integrate early evidence, and establish the operational backbone needed to scale, ensuring their innovations reach patients with clarity, speed, and impact.
With a strong entrepreneurial background, Alvin holds a Bachelor of Science in Finance from Babson College.
Alvin Mok
Chris Seagle., MBA, PhD
Chris leads market access, pricing, and health economics strategy, bringing experience from both global biopharma organizations and agile startups across oncology, immunology, and rare diseases. He specializes in developing scalable access solutions, evidence strategies, and governance frameworks that align clinical, medical, and commercial objectives.
With a reputation for collaborative leadership, Chris transforms market access into a strategic mindset—building partnerships that strengthen payer engagement, accelerate launch readiness, and ensure therapies are positioned for long-term value. His work bridges scientific depth with business strategy, drawing on a Ph.D. and M.S. in Biomedical Engineering, an MBA, and a B.S. in Chemistry to navigate complex healthcare systems with clarity and precision.
Chris is known for driving sustainable, evidence-based access solutions and helping teams adapt to evolving payer landscapes. His passion for change management and cross-functional alignment supports lasting impact for both patients and the industry.
Chris Seagle
Veron Browne, PhD
Chelsey Ali, PharmD
Chelsey Ali, PharmD
Veron leads our Translational and Clinical Strategy practice at ElevEx BioGroup. He is a pharmacologist, toxicologist, and life-sciences executive who advances therapies from discovery through clinical development. He specializes in translating complex data into clear development, regulatory, and commercial strategies that accelerate tim
Veron leads our Translational and Clinical Strategy practice at ElevEx BioGroup. He is a pharmacologist, toxicologist, and life-sciences executive who advances therapies from discovery through clinical development. He specializes in translating complex data into clear development, regulatory, and commercial strategies that accelerate timelines and strengthen portfolio value.
Dr. Browne advises pharmaceutical and biotech companies on development planning, toxicology, regulatory submissions, and translational science—streamlining IND/NDA readiness and aligning R&D with commercial objectives.
His leadership includes roles at Lundbeck, Pfizer (Wyeth-Ayerst), Transave, and MRI Global, with experience across neurology, oncology, immunology, and critical care. This multidisciplinary background enables him to bridge scientific rigor, patient impact, and business needs throughout the drug development lifecycle.
As Executive Director and Head of Preclinical & Clinical Development at Eagle Pharmaceuticals, he led IND-enabling programs and advanced multiple assets to FDA acceptance and first-in-human studies. At Memorial Sloan Kettering Cancer Center, he built a GLP-compliant facility that strengthened translational research and biomarker-driven programs.
Dr. Browne holds a B.S. in Biology and Chemistry (Franklin Pierce University), an M.Sc. in Industrial Pharmacy (Long Island University), and a Ph.D. in Pharmacology and Toxicology (University of the Sciences).
Chelsey Ali, PharmD
Chelsey Ali, PharmD
Chelsey Ali, PharmD
Chelsey is a PharmD and health economics (HEOR) researcher who specializes in real-world evidence, value demonstration, and market access strategy. With experience across industry and academia, including a Global HEOR Fellowship at Teva Pharmaceuticals. She brings a rigorous, data-driven approach to understanding unmet needs, communicati
Chelsey is a PharmD and health economics (HEOR) researcher who specializes in real-world evidence, value demonstration, and market access strategy. With experience across industry and academia, including a Global HEOR Fellowship at Teva Pharmaceuticals. She brings a rigorous, data-driven approach to understanding unmet needs, communicating value, and supporting evidence strategies that accelerate access to innovative therapies.
Her work spans RWE generation, HEOR strategy, value messaging, AMCP and HTA-ready dossiers, and targeted evidence synthesis. She has collaborated closely with clinical, medical, and market access teams to identify evidence gaps, shape development strategy, and support early engagement with payers and access stakeholders.
At ElevEx Bio, Chelsea applies her expertise to help emerging biopharma companies build the evidence foundations needed for market entry by aligning scientific data, patient insights, and payer expectations to strengthen value stories and support successful commercialization.
She holds a Doctor of Pharmacy (The University of Maryland School of Pharmacy) and a Master of Science in Applied HEOR (Jefferson College of Population Health).